The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice-Reference-Cited by-同舟云学术

The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice

Published:2019-04 Issue:4 Volume:60 Page:478-487
ISSN:1044-1549
Container-title:American Journal of Respiratory Cell and Molecular Biology
language:en
Short-container-title:Am J Respir Cell Mol Biol

Author:

Koyama Kazuya¹²,Goto Hisatsugu¹,Morizumi Shun¹,Kagawa Kozo¹,Nishimura Haruka¹,Sato Seidai¹,Kawano Hiroshi¹,Toyoda Yuko¹,Ogawa Hirohisa³,Homma Sakae²,Nishioka Yasuhiko¹

Affiliation:

1. Department of Respiratory Medicine and Rheumatology and

2. Department of Respiratory Medicine, Toho University Graduate School of Medicine, Tokyo, Japan

3. Department of Molecular and Environmental Pathology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan; and

Publisher

American Thoracic Society

Subject

Cell Biology,Clinical Biochemistry,Pulmonary and Respiratory Medicine,Molecular Biology

Link

https://www.atsjournals.org/doi/pdf/10.1165/rcmb.2018-0098OC

Reference48 articles.

1. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

2. Role of Platelet-Derived Growth Factor/Platelet-Derived Growth Factor Receptor Axis in the Trafficking of Circulating Fibrocytes in Pulmonary Fibrosis

3. Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis

4. Imatinib as a Novel Antifibrotic Agent in Bleomycin-induced Pulmonary Fibrosis in Mice

5. Role of α1-Acid Glycoprotein in Therapeutic Antifibrotic Effects of Imatinib with Macrolides in Mice

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways;European Journal of Medicinal Chemistry;2023-11

2. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond;Expert Opinion on Emerging Drugs;2023-10-02

3. Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis;Respiratory Investigation;2023-07

4. Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy;Scientific Reports;2023-05-31

5. Selective depletion of CD11b-positive monocytes/macrophages potently suppresses bleomycin-induced pulmonary fibrosis;International Immunopharmacology;2023-01